A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

182

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

October 30, 2030

Conditions

Multiple Sclerosis

Interventions

DRUG

Ocrelizumab Test Formulation

Ocrelizumab test formulation will be administered as per the schedule specified in the respective arm.

DRUG

Ocrelizumab Reference Formulation

Ocrelizumab reference formulation will be administered as per the schedule specified in the respective arm.

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY